Clinical Trial Spotlight Ewing Sarcoma | Children's National

Clinical Trial Spotlight Ewing Sarcoma | Children's National

Phase 1 dose escalation study looks at using TK216 to treat Ewing sarcoma A Phase 1 clinical trial at Children's National Hospital is looking at the safety and efficacy of using TK216 alone and in combination with vincristine for treating Ewing sarcoma. TK216 is a unique, investigational agent that inhibits the activity of ETS-family transcription factor oncoproteins in a variety of tumor types.